Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL
Karin Hohloch(University of Göttingen), Michael Pfreundschuh(Saarland University), Markus Löffler(University Children's Hospital Tübingen), Marita Ziepert(Leipzig University of Applied Sciences), Andreas Engert(University of Cologne), A. C. Feller(University of Lübeck), Ulrich Kaiser(University of Applied Sciences Landshut), Frank Kroschinsky(University Hospital Carl Gustav Carus), Rolf M. Mesters(University Hospital Münster), Carsten Zwick(Saarland University), Lorenz Trümper(University of Göttingen), Heinz‐Gert Höffkes(Klinikum Fulda), Dirk Hasenclever(Franklin University)
Cited by 10
Related Papers
Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study
|The Lancet|2020|1.8k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
|The Lancet Oncology|2008|1.1k
A Biologic Definition of Burkitt's Lymphoma from Transcriptional and Genomic Profiling
|New England Journal of Medicine|2006|1k